In vitro antibacterial activity of meropenem, a new carbapenem antibiotic

Yoshihiro Sumita, Susumu Mitsuhashi, Matsuhisa Inoue, Matsuhisa Inoue

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The in vitro activity of the new carbapenem, meropenem (MEPM) was tested in comparison with imipenem (IPM), ceftazidime, cefotaxime, latamoxef and flomoxef. MEPM showed good activity against a broad spectrum of gram-positive and gram-negative standard bacteria, including Pseudomonas aeruginosa. The activity of MEPM against gram-positive cocci was about one-fourth that of IPM. MEPM was highly active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except for 25% of Serratia marcescens isolates, at a concentration of 0.78 µg/ml. MEPM also showed a high activity against P. aeruginosa, its activity being two-fold higher than that of IPM. Against anaerobes, MEPM also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. MEPM also showed bactericidal activity against clinical isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Proteus vulgaris and P. aeruginosa at the MIC or at concentrations slightly above the MIC. MEPM was quite stable against various types of β-lactamase, but was hydrolyzed by X. maltophilia L-1 type β-lactamase, as were IPM and other β-lactams. This high degree of stability was responsible for the potent activity of MEPM against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and P. vulgaris.

Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalChemotherapy
Volume40
DOIs
Publication statusPublished - Jan 1 1992
Externally publishedYes

Fingerprint

meropenem
Carbapenems
Imipenem
Lactams
Pseudomonas aeruginosa
Proteus vulgaris
Stenotrophomonas maltophilia
Gram-Negative Bacteria
Citrobacter freundii
Moxalactam
Flavobacterium
In Vitro Techniques
Enterobacter cloacae
Gram-Positive Cocci
Enterococcus faecium
Serratia marcescens
Methicillin Resistance
Methicillin
Ceftazidime
Cefotaxime

Keywords

  • Meropenem
  • β-lactamase

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

In vitro antibacterial activity of meropenem, a new carbapenem antibiotic. / Sumita, Yoshihiro; Mitsuhashi, Susumu; Inoue, Matsuhisa; Inoue, Matsuhisa.

In: Chemotherapy, Vol. 40, 01.01.1992, p. 1-15.

Research output: Contribution to journalArticle

Sumita, Yoshihiro ; Mitsuhashi, Susumu ; Inoue, Matsuhisa ; Inoue, Matsuhisa. / In vitro antibacterial activity of meropenem, a new carbapenem antibiotic. In: Chemotherapy. 1992 ; Vol. 40. pp. 1-15.
@article{2f607e6aec2e4b5eb21676c06fb05c85,
title = "In vitro antibacterial activity of meropenem, a new carbapenem antibiotic",
abstract = "The in vitro activity of the new carbapenem, meropenem (MEPM) was tested in comparison with imipenem (IPM), ceftazidime, cefotaxime, latamoxef and flomoxef. MEPM showed good activity against a broad spectrum of gram-positive and gram-negative standard bacteria, including Pseudomonas aeruginosa. The activity of MEPM against gram-positive cocci was about one-fourth that of IPM. MEPM was highly active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except for 25{\%} of Serratia marcescens isolates, at a concentration of 0.78 µg/ml. MEPM also showed a high activity against P. aeruginosa, its activity being two-fold higher than that of IPM. Against anaerobes, MEPM also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. MEPM also showed bactericidal activity against clinical isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Proteus vulgaris and P. aeruginosa at the MIC or at concentrations slightly above the MIC. MEPM was quite stable against various types of β-lactamase, but was hydrolyzed by X. maltophilia L-1 type β-lactamase, as were IPM and other β-lactams. This high degree of stability was responsible for the potent activity of MEPM against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and P. vulgaris.",
keywords = "Meropenem, β-lactamase",
author = "Yoshihiro Sumita and Susumu Mitsuhashi and Matsuhisa Inoue and Matsuhisa Inoue",
year = "1992",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.40.Supplement1_1",
language = "English",
volume = "40",
pages = "1--15",
journal = "Chemotherapy",
issn = "0009-3165",

}

TY - JOUR

T1 - In vitro antibacterial activity of meropenem, a new carbapenem antibiotic

AU - Sumita, Yoshihiro

AU - Mitsuhashi, Susumu

AU - Inoue, Matsuhisa

AU - Inoue, Matsuhisa

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The in vitro activity of the new carbapenem, meropenem (MEPM) was tested in comparison with imipenem (IPM), ceftazidime, cefotaxime, latamoxef and flomoxef. MEPM showed good activity against a broad spectrum of gram-positive and gram-negative standard bacteria, including Pseudomonas aeruginosa. The activity of MEPM against gram-positive cocci was about one-fourth that of IPM. MEPM was highly active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except for 25% of Serratia marcescens isolates, at a concentration of 0.78 µg/ml. MEPM also showed a high activity against P. aeruginosa, its activity being two-fold higher than that of IPM. Against anaerobes, MEPM also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. MEPM also showed bactericidal activity against clinical isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Proteus vulgaris and P. aeruginosa at the MIC or at concentrations slightly above the MIC. MEPM was quite stable against various types of β-lactamase, but was hydrolyzed by X. maltophilia L-1 type β-lactamase, as were IPM and other β-lactams. This high degree of stability was responsible for the potent activity of MEPM against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and P. vulgaris.

AB - The in vitro activity of the new carbapenem, meropenem (MEPM) was tested in comparison with imipenem (IPM), ceftazidime, cefotaxime, latamoxef and flomoxef. MEPM showed good activity against a broad spectrum of gram-positive and gram-negative standard bacteria, including Pseudomonas aeruginosa. The activity of MEPM against gram-positive cocci was about one-fourth that of IPM. MEPM was highly active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except for 25% of Serratia marcescens isolates, at a concentration of 0.78 µg/ml. MEPM also showed a high activity against P. aeruginosa, its activity being two-fold higher than that of IPM. Against anaerobes, MEPM also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. MEPM also showed bactericidal activity against clinical isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Proteus vulgaris and P. aeruginosa at the MIC or at concentrations slightly above the MIC. MEPM was quite stable against various types of β-lactamase, but was hydrolyzed by X. maltophilia L-1 type β-lactamase, as were IPM and other β-lactams. This high degree of stability was responsible for the potent activity of MEPM against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and P. vulgaris.

KW - Meropenem

KW - β-lactamase

UR - http://www.scopus.com/inward/record.url?scp=0026633720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026633720&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.Supplement1_1

DO - 10.11250/chemotherapy1953.40.Supplement1_1

M3 - Article

AN - SCOPUS:0026633720

VL - 40

SP - 1

EP - 15

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -